What are the strategic and financial benefits of this transaction? This transaction achieves unique and complementary strategic objectives for both organizations. Combining Allergan’s diversified on-market product portfolio with AbbVie’s growth platform and deep expertise in R&D, commercial strength and international footprint will create a leading biopharmaceutical company with approximately$48 billion in combined 2019 revenue. This […]

GI-focused healthcare company Ironwood Pharmaceuticals has announced that it plans to relocate its headquarters to a new office in downtown Boston from its current location in Cambridge. Ironwood’s new headquarters will occupy approximately 39,000 square feet at 100 Summer Street. The new Boston headquarters is sized to fit the current employee base following completion of […]

Pfizer and Array BioPharma have announced Pfizer will acquire Array, a commercial stage biopharma with operations in Colorado, Massachusetts and North Carolina focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need. Pfizer has agreed to acquire Array for $48 per share in […]

Cambridge-based Comet Therapeutics has raised $28.5 million in Series A funding to develop a broad portfolio of drug candidates built around the unique ability to re-engineer Coenzyme A (CoA)-related metabolism. Comet’s platform has numerous potential applications including metabolic disorders, neuro-metabolic diseases, immuno-metabolic conditions and other life-threatening diseases. CoEnzyme A (CoA) is essential in numerous cellular […]

Merck has announced that it plans to acquire Lexington-based Tilos Therapeutics, a biopharma developing therapeutics targeting the latent TGFβ complex for the treatment of cancer, fibrosis and autoimmune diseases. TGFβ is a potent cytokine believed to play an important role in the development of cancer and fibrotic diseases. TGFβ is secreted as a complex with […]

Vertex and CRISPR Therapeutics have expanded their collaboration and entered into an exclusive licensing agreement to discover and develop gene editing therapies for the treatment of Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1). In addition, Vertex will acquire privately-held Exonics, a company focused on creating transformative gene editing therapies to repair mutations […]

bluebird bio has announced that the European Commission (EC) has granted conditional marketing authorization for Zynteglo™,  a gene therapy for certain patients with transfusion-dependent β-thalassemia (TDT). The authorization is valid in all 28 member states of the EU as well as Iceland, Liechtenstein and Norway. TDT is a severe genetic disease caused by mutations in the […]

Chicago-based, investment management firm Harrison Street has entered a ground lease with MIT for the three-building, 677K SF Osborn Triangle life science complex near Kendall Square. The deal surpassed $1B, or just over $1,600/SF, setting a neighborhood portfolio price record, according to sources familiar with the deal. “Osborn Triangle is a one-of-a-kind complex serving as […]

Vertex Pharmaceuticals and Kymera Therapeutics have announced that the two companies have entered into a four-year strategic research and development collaboration to advance small molecule protein degraders against multiple targets.  The collaboration will leverage Kymera’s expertise in targeted protein degradation and its proprietary PegasusTM drug discovery platform and Vertex’s scientific, clinical, and regulatory capabilities to […]

Gilead Sciences and Goldfinch Bio have announced a strategic collaboration to discover, develop and commercialize a pipeline of innovative therapeutics for diabetic kidney disease (DKD) and certain orphan kidney diseases. Under the multi-year collaboration, Gilead has exclusive options to license worldwide rights to certain products directed toward targets emerging from Goldfinch’s proprietary Kidney Genome Atlas™ (KGA), […]